Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pulmonx (LUNG) EBITDA (2019 - 2025)

Pulmonx has reported EBITDA over the past 7 years, most recently at -$14.4 million for Q3 2025.

  • Quarterly EBITDA fell 5.68% to -$14.4 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$57.0 million through Sep 2025, down 0.94% year-over-year, with the annual reading at -$56.9 million for FY2024, 4.78% up from the prior year.
  • EBITDA was -$14.4 million for Q3 2025 at Pulmonx, up from -$14.7 million in the prior quarter.
  • Over five years, EBITDA peaked at -$10.1 million in Q3 2021 and troughed at -$16.1 million in Q1 2022.
  • The 5-year median for EBITDA is -$14.4 million (2025), against an average of -$14.1 million.
  • Year-over-year, EBITDA tumbled 164.33% in 2021 and then grew 8.91% in 2024.
  • A 5-year view of EBITDA shows it stood at -$12.8 million in 2021, then decreased by 9.87% to -$14.1 million in 2022, then grew by 6.47% to -$13.2 million in 2023, then decreased by 3.06% to -$13.6 million in 2024, then dropped by 5.58% to -$14.4 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's EBITDA are -$14.4 million (Q3 2025), -$14.7 million (Q2 2025), and -$14.4 million (Q1 2025).